Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2752.47 | 1445 / 1445 | 100% | 27.08 | 183 / 183 |
liver | 100% | 1720.34 | 226 / 226 | 100% | 21.13 | 406 / 406 |
ovary | 100% | 1721.46 | 180 / 180 | 100% | 22.16 | 430 / 430 |
uterus | 100% | 2269.56 | 170 / 170 | 100% | 37.40 | 459 / 459 |
brain | 100% | 4277.84 | 2641 / 2642 | 100% | 36.68 | 705 / 705 |
breast | 100% | 2192.66 | 459 / 459 | 100% | 39.26 | 1116 / 1118 |
adrenal gland | 100% | 2809.10 | 258 / 258 | 100% | 30.92 | 229 / 230 |
bladder | 100% | 2869.33 | 21 / 21 | 99% | 29.33 | 501 / 504 |
prostate | 100% | 2255.98 | 244 / 245 | 100% | 27.17 | 501 / 502 |
lung | 99% | 1757.85 | 574 / 578 | 100% | 29.99 | 1155 / 1155 |
thymus | 100% | 1913.17 | 651 / 653 | 99% | 24.12 | 600 / 605 |
stomach | 100% | 2054.55 | 359 / 359 | 98% | 25.57 | 281 / 286 |
kidney | 100% | 1802.85 | 89 / 89 | 98% | 18.68 | 882 / 901 |
intestine | 100% | 2838.53 | 966 / 966 | 98% | 27.21 | 515 / 527 |
skin | 100% | 2325.06 | 1803 / 1809 | 96% | 26.07 | 454 / 472 |
pancreas | 96% | 892.73 | 315 / 328 | 99% | 20.13 | 176 / 178 |
blood vessel | 100% | 3331.99 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 22.01 | 29 / 29 |
muscle | 100% | 2603.34 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 1497.52 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 31.94 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 8.16 | 1 / 1 |
adipose | 100% | 2347.65 | 1203 / 1204 | 0% | 0 | 0 / 0 |
heart | 94% | 1181.39 | 811 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 83% | 17.98 | 66 / 80 |
peripheral blood | 39% | 931.78 | 358 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006282 | Biological process | regulation of DNA repair |
GO_0016567 | Biological process | protein ubiquitination |
GO_0000729 | Biological process | DNA double-strand break processing |
GO_0042275 | Biological process | error-free postreplication DNA repair |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0006301 | Biological process | postreplication repair |
GO_2000781 | Biological process | positive regulation of double-strand break repair |
GO_1902523 | Biological process | positive regulation of protein K63-linked ubiquitination |
GO_0070534 | Biological process | protein K63-linked ubiquitination |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0031372 | Cellular component | UBC13-MMS2 complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0005515 | Molecular function | protein binding |
Gene name | UBE2V2 |
Protein name | Ubiquitin-conjugating enzyme E2 variant 2 (DDVit 1) (Enterocyte differentiation-associated factor 1) (EDAF-1) (Enterocyte differentiation-promoting factor 1) (EDPF-1) (MMS2 homolog) (Vitamin D3-inducible protein) Ubiquitin conjugating enzyme E2 V2 Ubiquitin-conjugating enzyme E2 variant 2 |
Synonyms | hCG_1640505 MMS2 UEV2 |
Description | FUNCTION: Has no ubiquitin ligase activity on its own. The UBE2V2/UBE2N heterodimer catalyzes the synthesis of non-canonical poly-ubiquitin chains that are linked through 'Lys-63'. This type of poly-ubiquitination does not lead to protein degradation by the proteasome. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. . FUNCTION: Has no ubiquitin ligase activity on its own. The UBE2V2/UBE2N heterodimer catalyzes the synthesis of non-canonical poly-ubiquitin chains that are linked through 'Lys-63'. This type of poly-ubiquitination does not lead to protein degradation by the proteasome. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. . FUNCTION: Has no ubiquitin ligase activity on its own. The UBE2V2/UBE2N heterodimer catalyzes the synthesis of non-canonical poly-ubiquitin chains that are linked through 'Lys-63'. This type of poly-ubiquitination does not lead to protein degradation by the proteasome. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. . |
Accessions | ENST00000520595.2 ENST00000517630.5 H0YBX6 ENST00000521346.5 A0M8W4 G3V113 E5RIF1 ENST00000518360.5 ENST00000523111.7 Q15819 |